Wrap Text
Amendment to Loan Agreement with Eenhede Konsultante and directors’ participation in the PMA Capital Raise
ADVANCED HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2013/059246/06)
(“the Company” or “Advanced Health”)
ISIN Code: ZAE000189049 JSE Code: AVL
AMENDMENT TO LOAN AGREEMENT WITH EENHEDE KONSULTANTE AND DIRECTORS’
PARTICIPATION IN THE PMA CAPITAL RAISE
1 INTRODUCTION AND BACKGROUND
Shareholders are referred to the announcement released on SENS on 25 January 2022 which
advised that Presmed Australia (Proprietary) Limited (“PMA”), in which Advanced Health
owned 59.66%, embarked on a capital raising through which it would raise capital from its
existing shareholders (“PMA Capital Raise”). To participate in the PMA Capital Raise and to
maintain Advanced Health’s interest in PMA, the board of directors of Advanced Health (the
“Board”) approved the Company to subscribe for an additional 119 411 PMA ordinary shares
at a subscription price of AUD37.75 per PMA ordinary share, at a total consideration of
AUD4 507 826 (approximately ZAR50 254 597).
Shareholders are advised that the initial PMA Capital Raise was not fully subscribed to by the
existing PMA shareholders. The PMA shareholders who participated initially was allowed to
subscribe for additional PMA ordinary shares. The Board approved the Company to subscribe
for additional PMA ordinary shares to reach a total subscription of 120 168 PMA ordinary
shares at a subscription price of AUD37.75 per PMA ordinary share, equating to a total
consideration of AUD4 536 340 (approximately ZAR50 572 479) .
2 AMENDMENT OF LOAN AGREEMENT
As announced on SENS on 25 January 2022, Advanced Health, together with its 100% owned
subsidiary, Advanced Health South Africa (Proprietary) Limited (“AHSA”), entered into a new
loan agreement with Eenhede Konsultante (Proprietary) Limited (“Eenhede Konsultante”), for
Eenhede Konsultante to extend a shareholder’s loan of AUD4 507 826 (“Loan Amount”), to the
Company, for the purpose of participating in the PMA Capital Raise and to acquire the initial
119 411 PMA ordinary shares (“Loan Agreement”).
The Loan Agreement has, subsequent to the finalisation of the PMA Capital Raise, been
amended to increase the Loan Amount with an additional AUD28 514 (approximately ZAR
318 883) to AUD4 536 340 (approximately ZAR50 572 479). The additional PMA ordinary
shares have also been pledged to Eenhede Konsultante as security, in order to reflect the total
120 168 PMA ordinary shares, subscribed for as part of the PMA Capital Raise. The other key
terms of the Loan Agreement as disclosed in the SENS announcement dated 25 January 2022,
remains unchanged.
3 ACQUISITION OF AN ADDITIONAL 0.91% INTEREST IN PMA
As a result of the PMA Capital Raise, Advanced Heath’s interest in PMA has increased by
0.91%, from 59.66% to 60.57%. The total consideration attributable to this 0.91% increase is
AUD360 214 (approximately ZAR4 015 774), representing 9 542 PMA ordinary shares valued
at AUD 37.75 per PMA ordinary share.
4 ADVANCED HEALTH DIRECTORS’ PARTICIPATION IN PMA CAPITAL RAISE
Further to the participation of Advanced Health in the PMA Capital Raise, each of the following
directors of Advanced Health, who are shareholders of PMA, participated in the PMA Capital
Raise, resulting in their respective direct and indirect beneficial interest in PMA, increasing as
detailed below:
• Carl Alfred Grillenberger’s (non-executive Chairman of the Board), direct interest in PMA
increased with 0.03% from 1.69% to 1.72% (representing 270 PMA ordinary shares valued
at AUD10 205 (approximately ZAR113 764)).
• Cobus Visser’s (independent non-executive director of the Board), indirect interest in PMA
increased with 0.02% from 1.38% to 1.40% (representing 220 PMA ordinary shares valued
at AUD8 317 (approximately ZAR92 722)).
• Johan Oelofse’s (independent non-executive director of the Board until 12 November
2021), direct and indirect interests in PMA increased with 0.02% from 1.49% to1.51%
(representing 909 PMA shares valued at AUD34 298 (approximately ZAR(382 361)).
5 RELATED PARTY TRANSACTIONS
Eenhede Konsultante is an associate company of Carl Alfred Grillenberger, the Chairman of
the Board and the majority shareholder of the Company, with an indirect beneficial interest
of 71.1%, through Eenhede Konsultante together with Pres Medical Witbank, Carl
Grillenberger Family Trust and the VC Family Trust. Eenhede Konsultante is therefore a related
party to the Company as defined in Section 10 the JSE Listings Requirements.
Carl Grillenberger and Cobus Visser, as directors of the Board, and Johan Oelofse, who was a
director in the past 18 months, are related parties to the Company as defined in Section 10 of
the JSE Listings Requirements.
6 CATEGORISATION OF THE TRANSACTIONS
6.1 Amendment of the Loan Agreement
Pursuant to section 10 of the JSE Listings Requirements read with section 21, the Loan
Agreement and the subsequent amendment thereof, is categorised as a small related party
transaction for AltX issuers and therefore, is not subject to Advanced Health shareholder
approval.
6.2 Acquisition of an additional 0.91% interest in PMA
The acquisition of the additional 0.91% interest in PMA by Advanced Health is not
categorizable as a transaction in terms of section 9 of the JSE Listings Requirements.
6.3 Advanced Health Directors’ Participation in PMA Capital Raise
The participation in the PMA Capital Raise by each of Carl Grillenberger, Cobus Visser and
Johan Oelofse, resulting in their respective interests in PMA increasing, as detailed in
paragraph 4 above, are categorised below the small related party transaction threshold in
terms of section 10 of the JSE Listings Requirements read with section 21, and are therefore
not subject to a Fairness Opinion or Advanced Health shareholder approval.
7 FAIRNESS OPINION REGARDING THE AMENDMENT OF THE LOAN AGREEMENT
As per the SENS announcement dated 25 January 2022, Advanced Health appointed BDO
Corporate Finance Proprietary Limited (“BDO”) to provide a fairness opinion with regards to
the Loan Agreement. BDO concluded that the terms and conditions of the Loan Agreement is
more favourable to Advanced Health than market related terms and conditions and therefore
the Loan Agreement is fair to Advanced Health shareholders.
BDO has considered the amendments to the Loan Agreement and its conclusion that it is fair
to Advanced Health shareholders, remains unchanged.
The Board confirms that it is of the opinion that the terms of the amended Loan Agreement is
fair insofar as Advanced Health shareholders are concerned, having regard to the BDO fairness
opinion. Copies of the BDO fairness opinion is available for inspection at Advanced Health
offices (Building 2, Walker Creek Office Park, 90 Florence Ribeiro Avenue, Muckleneuk,
Pretoria) and on the website https://advancedhealth.co.za for a further period of 28 days from
the date of this announcement.
8 BAGROUND TO PMA
Presmed Australia is one of the leading healthcare companies in Australia that specializes in
establishment and management of surgical day hospitals.
9 PROFIT AND NET ASSET VALUE ATTRIBUTABLE TO PMA
The net assets of PMA, as per the Advanced Health interim financial statements for the 6
months ended 31 December 2021 was ZAR234.7 million. The profit after tax attributable to
the net assets of PMA was ZAR22.7 million. The interim financial statements were prepared
in accordance with International Reporting Standards, the SAICA Financial Reporting Guides
as issued by the Accounting Practices Committee, the JSE Listing Requirements and the
Companies Act 71 of 2008 of South Africa.
Pretoria
11 March 2022
Designated Advisor
Grindrod Bank Limited
Date: 11-03-2022 03:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
